Latest Monoclonal antibodies Stories
Physicians Indicate that Switching of Currently Treated Patients to Biosimilar Infliximab Is Likely to be Limited, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
-- Polyarticular juvenile idiopathic arthritis (JIA) occurs in approximately 25 percent of all JIA patients NORTH CHICAGO, Ill., Oct.
AbGenomics raised new fund for advancing its mid-stage clinical trials LOS ALTOS, Calif., Oct.
SAN DIEGO, Oct. 3, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
The Firm is evaluating legal claims on behalf of individuals who allegedly suffered serious Xolair side effects, including heart attacks, mini-strokes, pulmonary hypertension, and blood clots
Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct.
On September 26, the FDA issued a safety communication on potential risks of cardiovascular and cerebrovascular serious adverse events to Xolair's (omalizumab) drug label.
SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- Lpath, Inc.
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators
More Images (1 images) »